---
title: "Obefazimod (ABX464) in Ulcerative colitis: Colectomy"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Colectomy. Topics: Indications for surgical consultation and colectomy: ACG 2025; ECCO 2026 surgical guideline: timing, reconstruction, and center volume; Cumulative risk of colectomy: meta-analysis of population-based cohorts; Cumulative risk of colectomy in newly diagnosed U.S. adults, 2007 to 2023; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/colectomy"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Colectomy

<a id="heading-2.2.2.1.11"></a>

## 2.2.2.1.11 Colectomy

<a id="topic-2.2.2.1.11-1"></a>

### Indications for surgical consultation and colectomy: ACG 2025

> “Obtain consultation with a surgeon and consider colectomy in patients with moderately to severely active UC who are refractory or intolerant to medical therapy.”
> “Patients with moderately to severely active UC who do not maintain remission despite optimized medical therapy should be considered for elective proctocolectomy.”
> “Toxic megacolon, colonic perforation, severe refractory hemorrhage, and refractoriness to medical therapy are indications for surgery in patients with ASUC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.11-2"></a>

### ECCO 2026 surgical guideline: timing, reconstruction, and center volume

> “We recommend surgical treatment when moderately-to-severely active UC is refractory to optimised medical therapy [EL3] [Agreement 97.5%]”
> “Despite major advances in medical therapy, colectomy rates in UC have remained largely unchanged,”
> “Conversely, delaying surgery increases the risk of emergency colectomy, which is associated with higher rates of postoperative complications, prolonged hospitalization, and increased mortality.”
> “While IPAA remains the standard of care [EL3], IRA is an option for selected patients.”
> “We recommend that reconstructive surgery after colectomy for UC with IPAA should be performed in specialized centers by experienced surgeons [EL4] [Agreement 97.5%]”
> “Although definitions vary, a minimum institutional volume of eight IPAA procedures per year has been proposed as a threshold for improved outcomes,”

Source: [Adamina et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/6/jjag072/8722674)

<a id="topic-2.2.2.1.11-3"></a>

### Cumulative risk of colectomy: meta-analysis of population-based cohorts

> “On meta-analysis, the cumulative risk of colectomy 1-, 5-, and 10-years after diagnosis was 4.0% (95% CI, 3.3–5.0), 8.8% (95% CI, 7.7–10.0) and 13.3% (95% CI, 11.3–15.5), respectively, with considerable heterogeneity (I2=95–98%) (Figures 1A–C).”

Source: [Tsai et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8934200/)

<a id="topic-2.2.2.1.11-4"></a>

### Cumulative risk of colectomy in newly diagnosed U.S. adults, 2007 to 2023

> “Cumulative 5y risk of colectomy was lower in the more contemporary cohort (patients diagnosed in 2019–23 vs. 2007–12: 4.2% vs. 6.7%; aHR, 0.58 [95% CI, 0.38–0.89]) (Figure 2E).”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-2.2.2.1.11-5"></a>

### Hospitalization cost of nonelective colectomy in the United States

> “An estimated 10,280 patients met study criteria with median index hospitalization costs of $40,300 (IQR, $26,400-$65,000). Increased time to surgery was significantly associated with a +$2500 increment in costs per day.”

Source: [Ng et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38583900/)

<a id="topic-2.2.2.1.11-6"></a>

### Colectomy cost input in the ICER 2020 model

> “A cost of $33,871 per admission for colectomy is assumed”

Source: [ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_UC_Final_Evidence_Report_101620.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
